Who Paid My Doc
Teodoro Jerves Serrano
Clinical Biochemical Genetics New Haven, CT Medical Doctor
NPI 1376098095 CMS profile 11457592
1 Long Wharf Dr, New Haven, CT 06511
General payments
$16
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Teodoro Jerves Serrano of New Haven, CT is reported in the CMS Open Payments database as having received $16 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $16 | 1 |
Beside peers
- Teodoro Jerves Serrano
- Clinical Biochemical Genetics median
- Middle half of Clinical Biochemical Genetics
- National median
In program year 2025, general payments to Teodoro Jerves Serrano were reported at $0. Among 23 Clinical Biochemical Genetics profiles paid that year, the median was $237 and the middle half received between $88 and $2,648.
Show as a table
| Year | Teodoro Jerves Serrano | Clinical Biochemical Genetics median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $132 | $20–$1,451 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | — | — | $132 |
| 2022 | $0 | $157 | $94–$2,848 | $149 |
| 2023 | $0 | $242 | $71–$1,706 | $160 |
| 2024 | $16 | — | — | $164 |
| 2025 | $0 | $237 | $88–$2,648 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$2,258
Medicare patients
17
Services billed
20
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 71% | |
| Alzheimer's or dementia | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| DAXXIFY |
|
$16 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Biochemical Genetics in Connecticut
Related records
Clinical Biochemical Genetics in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Biochemical Genetics
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.